Latest California Healthline Stories
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don’t have to.
Klobuchar Says D.C. Has Enough Drug Lobbyists To Double-Team Lawmakers
The drug industry has the biggest lobbying war chest.
GOP Senators Distance Themselves From Grassley And Trump’s Efforts To Cut Drug Prices
Even some Republicans who supported a sweeping bipartisan bill to rein in drug costs may not back it in the Senate vote.
KHN’s ‘What The Health?’: Cue The Drug Price Debate
Democrats and Republicans on the Senate Finance Committee unveiled their long-awaited proposal to try to rein in prescription drug costs, even as bipartisan leaders of the other Senate committee that oversees health announced it would not bring its drug price bill to the Senate floor until fall. Paige Winfield Cunningham of The Washington Post, Rebecca Adams of CQ Roll Call and Alice Miranda Ollstein of Politico join KHN’s Julie Rovner to discuss this, plus court actions on health issues.
A Conservative Group Paints Trump’s Drug-Pricing Experiment As ‘Socialist.’ Is It?
The Americans for Tax Reform commercial takes too broad a brush against an initiative under consideration by the administration that would be part of the president’s promise to curb high drug prices.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don’t have to.
KHN’s ‘What The Health?’: Biden Doubles Down On Obamacare
Presidential candidate Joe Biden unveiled a health plan intended to provide a more moderate alternative to his competitors’ “Medicare for All” plans. It would build on the Affordable Care Act but would go much further. Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and Kimberly Leonard of the Washington Examiner join KHN’s Julie Rovner to discuss this, plus Planned Parenthood’s very bad week, the U.S. House vote to repeal the health law’s “Cadillac tax” on generous health plans, and the reduction in deaths from opioids.
A ‘No-Brainer’? Calls Grow For Medicare To Cover Anti-Rejection Drugs After Kidney Transplant
Banking on new cost estimates, a bipartisan coalition in Congress is poised to try — once again — to end a three-year limit on coverage for lifesaving medication required to keep the organs functioning.
Costos adicionales bloquean el tratamiento para prevenir el VIH
Aunque muchas aseguradoras cubren PrEP, los costos por las pruebas adicionales que hay que realizarse pueden bloquear el acceso a esta terapia preventiva.
Even When HIV Prevention Drug Is Covered, Other Costs Block Treatment
The U.S. Preventive Services Task Force recommended that people who are at high risk of contracting HIV take PrEP, a preventive treatment. The decision means most health plans will be required to cover the drugs without charging patients. But the recommendation doesn’t apply to the other clinical and lab services people need.